These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 541259)

  • 21. [Comparative activity of habekacin and 4 other aminoglycosides against gram-negative bacilli. Evolution of resistance].
    Reynaud AE; Coude du Foresto B; Derriennic M; Courtieu AL
    Pathol Biol (Paris); 1988 May; 36(5):435-8. PubMed ID: 3136424
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis of 2''-amino-2''-deoxyarbekacin and its analogs having potent activity against methicillin-resistant Staphylococcus aureus.
    Kondo S; Ikeda Y; Ikeda D; Takeuchi T; Usui T; Ishii M; Kudo T; Gomi S; Shibahara S
    J Antibiot (Tokyo); 1994 Jul; 47(7):821-32. PubMed ID: 8071128
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Animal experiments on the nephrotoxicity, pharmacokinetics and therapeutic efficacy of dibekacin].
    Bopp S; Marre R; Schulz E; Sack K
    Arzneimittelforschung; 1981; 31(3):473-7. PubMed ID: 7194672
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sisomicin, netilmicin and dibekacin. A review of their antibacterial activity and therapeutic use.
    Noone P
    Drugs; 1984 Jun; 27(6):548-78. PubMed ID: 6376062
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Investigation in vitro synergism on ampicillin with cloxacillin and dibekacin against glucose non-fermenting gram-negative bacilli and Serratia (author's transl)].
    Deguchi K
    Jpn J Antibiot; 1978 Oct; 31(10):610-3. PubMed ID: 366194
    [No Abstract]   [Full Text] [Related]  

  • 26. Amikacin, an aminoglycoside with marked activity against antibiotic-resistant clinical isolates.
    Price KE; DeFuria MD; Pursiano TA
    J Infect Dis; 1976 Nov; 134 SUPPL():S249-61. PubMed ID: 62814
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of varying the 4''-position of arbekacin derivatives on antibacterial activity against MRSA and Pseudomonas aeruginosa.
    Hiraiwa Y; Minowa N; Usui T; Akiyama Y; Maebashi K; Ikeda D
    Bioorg Med Chem Lett; 2007 Nov; 17(22):6369-72. PubMed ID: 17889537
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Comparative activity of dibekacin and several cephalosporins on Pseudomonas aeruginosa].
    Carlone NA; Cuffini AM; Forno-Pizzoglio M; Aragno M
    G Batteriol Virol Immunol; 1983; 76(7-12):246-56. PubMed ID: 6099297
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interaction of 3',4'-dideoxykanamycin B and submaxillary mucin.
    Aramaki Y; Niibuchi J; Tsuchiya S; Hosoda J
    Chem Pharm Bull (Tokyo); 1987 Jan; 35(1):320-5. PubMed ID: 3594663
    [No Abstract]   [Full Text] [Related]  

  • 30. [Synergistic effect of new beta-lactam antibiotics, clavulanic acid and dibekacin on pathogenic microorganisms].
    Jastalska D; Lupicki W; Zapaśnik M; Pajchel G; Chojnowski W
    Pol Tyg Lek; 1984 Oct; 39(43):1415-8. PubMed ID: 6440130
    [No Abstract]   [Full Text] [Related]  

  • 31. Synthesis and antibacterial activities of 1-N [(S)-omega-amino-2-hydroxyalkyl] kanamycin A derivatives.
    Richardson K; Jevons S; Moore JW; Ross BC; Wright JR
    J Antibiot (Tokyo); 1977 Oct; 30(10):843-6. PubMed ID: 591447
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interaction of 3',4'-dideoxykanamycin B with a lysosomal enzyme, N-acetyl-beta-D-glucosaminidase.
    Aramaki Y; Inaba A; Niibuchi J; Tsuchiya S
    Chem Pharm Bull (Tokyo); 1983 Jan; 31(1):321-4. PubMed ID: 6850946
    [No Abstract]   [Full Text] [Related]  

  • 33. Neuromuscular blocking activity of dibekacin, a new semisynthetic aminoglycoside antibiotic.
    Paradelis AG; Tsouras JS; Latsoudes P; Demetriou T; Triantaphyllidis C
    Experientia; 1980 Jul; 36(7):867-8. PubMed ID: 6772469
    [No Abstract]   [Full Text] [Related]  

  • 34. [Development of arbekacin and synthesis of new derivatives stable to enzymatic modifications by methicillin-resistant Staphylococcus aureus].
    Kondo S
    Jpn J Antibiot; 1994 Jun; 47(6):561-74. PubMed ID: 8072163
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synergistic effects of L-azaserine on dibekacin against Escherichia coli and Staphylococcus aureus.
    Yamabe S; Aoyama T; Kurumi M; Gasha M
    J Antimicrob Chemother; 1980 Jul; 6(4):564-5. PubMed ID: 7000744
    [No Abstract]   [Full Text] [Related]  

  • 36. A newly recognized acetylated metabolite of arbekacin in arbekacin-resistant strains of methicillin-resistant Staphylococcus aureus.
    Fujimura S; Tokue Y; Takahashi H; Nukiwa T; Hisamichi K; Mikami T; Watanabe A
    J Antimicrob Chemother; 1998 Apr; 41(4):495-7. PubMed ID: 9598784
    [No Abstract]   [Full Text] [Related]  

  • 37. Synthesis of 2"-oxidized derivatives of 5-deoxy-5-epi-5-fluoro-dibekacin and -arbekacin, and study on structure-chemical shift relationships of urethane(or amide)-type NH protons in synthetic intermediates.
    Kobayashi Y; Tsuchiya T
    Carbohydr Res; 1997 Mar; 298(4):261-77. PubMed ID: 9098957
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthesis and antibacterial activity of 4″ or 6″-alkanoylamino derivatives of arbekacin.
    Sasaki K; Kobayashi Y; Kurihara T; Yamashita Y; Takahashi Y; Miyake T; Akamatsu Y
    J Antibiot (Tokyo); 2015 Dec; 68(12):741-7. PubMed ID: 25990952
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Therapy of surgical infections with dibekacin. Pharmacokinetic, clinical and bacteriological results].
    Sievers U; von Kobyletzki D; Primavesi CA
    Fortschr Med; 1980 Nov; 98(42):1667-70. PubMed ID: 7461562
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Comparative study on intravenous drip infusion of dibekacin once daily and twice daily in treatment of complicated urinary tract infections].
    Kishi H; Kaneco H; Tominaga T; Niijima T; Nishimura Y; Saito I; Ishii Y; Nito H; Yuge J; Asano M
    Hinyokika Kiyo; 1984 Jan; 30(1):103-20. PubMed ID: 6375317
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.